Pediatrics (System-Integrated)

Short stature: workup

Clinical Overview and When to Suspect Short Stature

— Mid-parental height (MPH): boys = [(maternal + paternal ht) + 13 cm]/2; girls = [(maternal + paternal ht) – 13 cm]/2; target range ±8.5 cm.

— Height <–2.5 SD or markedly below MPH

— Decelerating growth velocity (<5 cm/yr ages 4–puberty)

— Disproportionate body segments (upper:lower ratio abnormal, short limbs/trunk)

— Dysmorphic features, midline defects, micropenis (suggests hypopituitarism)

— Systemic symptoms: diarrhea, fatigue, polyuria, headaches, vision changes

— Delayed bone age plus poor growth velocity

— Familial short stature: normal velocity, normal bone age, height tracks MPH, normal puberty timing

— Constitutional delay of growth and puberty (CDGP): normal velocity, delayed bone age, delayed puberty, "late bloomer" family history, eventually reaches normal adult height

Definition: Height <3rd percentile (or <–2 SD) for age/sex on CDC growth charts, OR a growth velocity that has crossed ≥2 major percentile lines after age 2, OR height significantly below mid-parental target.

Why it matters on Step 3: The pediatrician must distinguish normal variants (familial short stature, constitutional delay) from pathologic causes (endocrine, GI, renal, syndromic, psychosocial) before reflexively referring or imaging.

When to suspect a pathologic cause:

Normal variants (most common):

Step 3 management: Before ordering labs, plot ≥3 accurate serial heights on the CDC chart, calculate growth velocity, calculate MPH, and obtain bone age (left hand/wrist X-ray). These four data points triage 80% of referrals.

Board pearl: A child whose height is low but velocity is normal and parallel to the curve almost always has a normal variant; a child falling off the curve needs a pathologic workup regardless of absolute height.

Presentation Patterns and Key History

— Birth weight/length, gestational age, SGA (small for gestational age — failure of catch-up by age 2 is an FDA indication for GH)

— Maternal smoking, alcohol, infections (TORCH), placental insufficiency

— Neonatal hypoglycemia, prolonged jaundice, micropenis, midline defects → think congenital hypopituitarism/GH deficiency

— Symmetric short stature from birth: genetic, syndromic (Turner, Noonan, skeletal dysplasias), IUGR

— Normal early growth, then deceleration ages 6–10: acquired endocrine (hypothyroidism, GH deficiency, Cushing), celiac, IBD, chronic illness

— Normal height but delayed pubertal growth spurt: CDGP

— GI: chronic diarrhea, bloating, abdominal pain → celiac, IBD

— Renal: polyuria, polydipsia, enuresis → RTA, chronic kidney disease

— Endocrine: cold intolerance, constipation, fatigue → hypothyroidism; weight gain + slow growth → Cushing; headaches/visual field defects → pituitary tumor (craniopharyngioma)

— Psychosocial: neglect, food insecurity → psychosocial dwarfism

— Parental heights (measured, not reported), parental pubertal timing (menarche, growth into 20s)

— Consanguinity, skeletal dysplasias, autoimmune disease, celiac

Birth and prenatal history:

Growth pattern timing — the most diagnostic clue:

Review of systems (target organ clues):

Family history:

Medication/nutrition history: chronic glucocorticoids, stimulants (modest effect), restrictive diets, food insecurity.

Key distinction: A child with slow growth AND weight loss first suggests caloric insufficiency or GI disease (weight drops before height); a child with slow growth AND relative weight preservation/obesity suggests endocrine disease (hypothyroidism, GH deficiency, Cushing) — endocrine kids are typically short and chubby, malnutrition kids are short and thin.

Physical Exam Findings and Anthropometric Assessment

— <2 years: recumbent length on a stadiometer board

— ≥2 years: standing height with stadiometer, shoes off, heels/back/head against wall

— Plot height, weight, BMI, head circumference (<3 yr) on CDC charts; use Down, Turner, achondroplasia-specific charts when indicated

— Upper-to-lower segment ratio: measure pubic symphysis to floor (lower); height – lower = upper. Normal: ~1.7 at birth, ~1.0 at age 10, ~0.95 adult

— Arm span vs height

— Short-limbed (high U:L): achondroplasia, hypochondroplasia

— Short-trunked (low U:L): spondyloepiphyseal dysplasia, mucopolysaccharidoses

— Turner: webbed neck, low posterior hairline, broad shield chest, widely spaced nipples, cubitus valgus, lymphedema, low-set ears

— Noonan: similar to Turner but in boys/girls, pulmonic stenosis, ptosis

— Russell-Silver: triangular facies, hemihypertrophy, 5th finger clinodactyly

— Achondroplasia: macrocephaly, frontal bossing, trident hand

— Hypothyroidism: goiter, dry skin, delayed reflexes, bradycardia

— Cushing: moon facies, buffalo hump, striae, central obesity with linear growth arrest

— GH deficiency: cherubic facies, increased adiposity, midline defects (cleft lip/palate, single central incisor)

— Delayed puberty + delayed bone age in an otherwise healthy adolescent → CDGP

— Pubertal stage out of sync with bone age → endocrine pathology

Accurate measurement is non-negotiable:

Body proportions (key for skeletal dysplasias):

Dysmorphic exam (syndrome screen):

Endocrine clues:

Pubertal staging (Tanner) — essential:

Board pearl: Always palpate the thyroid and assess visual fields in any child with growth deceleration — hypothyroidism and craniopharyngioma are classic high-yield missed diagnoses.

Diagnostic Workup — Initial Labs and Imaging

— Bone age = chronological age: familial short stature or normal

— Bone age < chronological age (delayed): CDGP, endocrine disease, chronic illness, malnutrition

— Bone age > chronological: precocious puberty, congenital adrenal hyperplasia (not a short stature picture initially but compromises adult height)

— CBC with diff — anemia, leukopenia (chronic disease, IBD)

— CMP — BUN/Cr (CKD), bicarbonate (RTA), calcium/phos/alk phos (rickets, dysplasia), LFTs

— ESR/CRP — IBD, chronic inflammation

— TSH and free T4 — hypothyroidism (cheap, high yield)

— Tissue transglutaminase IgA + total IgA — celiac disease (a leading "silent" cause)

— UA — RTA, occult renal disease

— IGF-1 and IGFBP-3 — surrogate for GH status (interpret per age; low nutrition lowers IGF-1)

— Karyotype in all girls with unexplained short stature — Turner syndrome (45,X) can present without classic features

— 25-OH vitamin D, ferritin — if nutrition concerns

— Brain MRI with pituitary protocol if GH deficiency suspected, midline defects, headaches, visual changes, or multiple pituitary hormone deficiencies

— Skeletal survey if disproportionate features → skeletal dysplasia

Step 1 — Bone age (left hand/wrist X-ray, read by Greulich-Pyle):

Step 2 — Screening labs (cast a wide net for occult disease):

Step 3 — Imaging beyond bone age:

Step 3 management: In a previously well girl with short stature and no dysmorphic features, still send a karyotype — mosaic Turner can lack the classic phenotype, and missing it costs years of untreated growth potential and unrecognized gonadal failure.

Board pearl: Celiac and hypothyroidism are the most commonly missed treatable causes — both have low-cost screening labs and are required first-line.

Diagnostic Workup — Advanced and Confirmatory Studies

— Random GH is useless (pulsatile secretion)

— GH provocation/stimulation testing: two agents (clonidine, arginine, insulin, glucagon, L-dopa) — GH peak <10 ng/mL on two stimuli confirms GH deficiency

— Always check other pituitary hormones (TSH, cortisol/ACTH, LH/FSH, prolactin) before stim testing — untreated central hypothyroidism or adrenal insufficiency invalidates results and is dangerous

— SHOX gene (chromosome Xp): mutations cause Léri-Weill dyschondrosteosis and isolated short stature; FDA approves GH for SHOX deficiency

— Targeted panels for Noonan (PTPN11, SOS1, RAF1), Russell-Silver (11p15, UPD7), skeletal dysplasias (FGFR3 for achondroplasia)

— Microarray/whole-exome for syndromic short stature with developmental delay

— Positive TTG-IgA → EGD with duodenal biopsy to confirm

— Elevated fecal calprotectin → colonoscopy for IBD

— Suspected Cushing: 24-hr urine free cortisol, late-night salivary cortisol, low-dose dexamethasone suppression

— Suspected precocious or delayed puberty: LH/FSH, estradiol/testosterone, GnRH stimulation

GH axis testing (when IGF-1/IGFBP-3 are low and screening labs unrevealing):

Pituitary MRI: confirmed GHD → image to find ectopic posterior pituitary, pituitary stalk interruption syndrome, craniopharyngioma, empty sella

Genetic testing:

GI workup if celiac/IBD suspected:

Endocrine confirmatory:

Key distinction: IGF-1 generation test distinguishes GH deficiency (low IGF-1 that rises with exogenous GH) from GH insensitivity/Laron syndrome (low IGF-1 that does not rise — GHR mutation; treated with recombinant IGF-1, not GH).

Board pearl: Before any GH stim test, confirm euthyroid and replete cortisol — failing to do so leads to false-positive GHD diagnoses and missed adrenal crisis under insulin tolerance testing.

Risk Stratification and First-Line Management Logic

— Normal labs, normal velocity, bone age = chronologic, height tracks MPH: Familial short stature → reassure, monitor q6–12 months

— Normal labs, normal velocity, delayed bone age, delayed puberty, family history of late bloomers: CDGP → reassure; consider short-course androgen/estrogen priming if psychosocial distress in adolescents ≥14 (boys) or ≥13 (girls) with no spontaneous puberty

— Abnormal screening lab: treat underlying cause (levothyroxine for hypothyroidism, gluten-free diet for celiac, etc.) and reassess growth in 6–12 months — most show catch-up

— Low IGF-1, slow velocity, no systemic cause: refer to pediatric endocrinology for GH stim testing

— Disproportionate or dysmorphic: refer to genetics

— Turner syndrome

— SGA without catch-up by age 2

— Idiopathic short stature (height <–2.25 SD with predicted adult height <5'3" male/4'11" female)

— SHOX deficiency

— Prader-Willi syndrome

— Noonan syndrome

— Chronic kidney disease pre-transplant

Decision tree after initial workup:

FDA-approved indications for recombinant human GH in non-deficient children:

Step 3 management: Start GH only after confirmed indication, open growth plates (bone age <14 girls / <16 boys), and counseling on cost, daily SC injections, and modest height gain (3–7 cm) for non-deficient indications. Document realistic expectations.

When NOT to give GH: active malignancy, severe obesity with sleep apnea (Prader-Willi caveat), critical illness, closed epiphyses, uncontrolled diabetes.

Board pearl: Idiopathic short stature gains less height per year of GH than true GHD — set family expectations early; the goal is final adult height, not rapid catch-up.

Pharmacotherapy — First-Line Regimens

— Dose: GHD 0.16–0.24 mg/kg/week SC; Turner/ISS/SGA 0.24–0.35 mg/kg/week divided daily SC at bedtime

— Long-acting weekly formulations (somatrogon, lonapegsomatropin) now FDA-approved — improve adherence

— Monitor: height/velocity q3–6 months, IGF-1 q6–12 months (keep within age-normal range; high IGF-1 = reduce dose), TSH/free T4 (GH unmasks central hypothyroidism), fasting glucose/HbA1c, scoliosis exam, fundoscopy for IIH symptoms

— Stop GH when growth velocity <2 cm/yr or bone age >14 (girls) / >16 (boys), or near-final height achieved

— Weight-based dosing (~4–6 mcg/kg/day in young children, tapering)

— Recheck TSH/free T4 in 6–8 weeks; expect dramatic catch-up growth

— Boys: testosterone enanthate 50–100 mg IM monthly × 4–6 months

— Girls: low-dose transdermal estradiol for 6–12 months

— Does not compromise final adult height; jumpstarts puberty

Recombinant human growth hormone (somatropin):

Levothyroxine (if hypothyroidism is the cause):

Sex steroid priming for CDGP (adolescents with psychosocial distress):

IGF-1 (mecasermin) for Laron syndrome / severe primary IGF-1 deficiency: BID SC, monitor for hypoglycemia

Gluten-free diet for celiac — strict adherence drives catch-up growth within 6–12 months

Glucocorticoid management in Cushing-related growth failure: identify and treat source (taper exogenous steroids, surgery for endogenous)

Step 3 management: When starting GH, screen and treat central hypothyroidism first; GH increases T4→T3 conversion and clears cortisol faster, unmasking adrenal insufficiency in panhypopituitary patients — start hydrocortisone replacement before GH if any cortisol concern.

Board pearl: Long-acting weekly GH has equivalent efficacy to daily and dramatically improves adherence — relevant for value-based pediatric care.

Specialty Interventions and Surgical Considerations

— Craniopharyngioma/pituitary tumor: transsphenoidal resection by pediatric neurosurgery; postop panhypopituitarism is the rule — replace cortisol first, then thyroid, then GH, then sex steroids at puberty; DDAVP for DI

— Skeletal dysplasias (achondroplasia): vosoritide (CNP analog, daily SC) for children ≥5 years with open epiphyses — increases annualized growth velocity ~1.6 cm/yr; limb-lengthening surgery is controversial and offered selectively

— Turner syndrome: GH +/– oxandrolone in late childhood; estrogen replacement starting ~age 11–12 to induce puberty; cardiology surveillance (bicuspid aortic valve, coarctation)

— Prader-Willi: GH improves height, body composition, cognition; mandatory polysomnography before and after GH initiation — risk of sudden death from obstructive sleep apnea

— Aromatase inhibitors (letrozole, anastrozole) in boys with CDGP or ISS to delay epiphyseal fusion — not FDA-approved, off-label, monitor for vertebral changes

— GnRH agonists to delay puberty and extend growth window in select cases

— Pediatric endocrinology (primary)

— Genetics (syndromic/dysplasia)

— GI (celiac/IBD)

— Nutrition (caloric optimization)

— Mental health (body image, adherence, psychosocial dwarfism)

— Orthopedics (scoliosis, slipped capital femoral epiphysis — GH-associated)

Surgical and procedural considerations:

Adjunctive therapies under investigation:

Multidisciplinary team:

CCS pearl: For a child newly diagnosed with panhypopituitarism after craniopharyngioma resection, the CCS-correct order is: hydrocortisone first → levothyroxine → DDAVP as needed → GH once stable → sex steroids at pubertal age. Starting thyroid before cortisol can precipitate adrenal crisis.

Board pearl: Vosoritide is the first targeted pharmacotherapy for achondroplasia — high-yield new agent.

Special Populations — Renal, Hepatic, and Chronic Disease

— Growth failure from acidosis, renal osteodystrophy, anemia, GH resistance, protein-energy wasting

— Optimize before GH: correct metabolic acidosis (bicarb >22), treat renal osteodystrophy (calcium, phosphate binders, active vitamin D), treat anemia (iron, ESA to Hb 11–12), ensure adequate caloric intake

— GH dosing in CKD: 0.05 mg/kg/day (higher than GHD) — overcomes GH resistance

— Hold GH peri-transplant; resume after stable graft function

— Malnutrition, fat-soluble vitamin deficiency, IGF-1 produced by liver — low IGF-1 with normal/high GH = GH resistance

— Treat underlying disease; GH not effective until transplant

— Both malabsorption and inflammatory cytokine-mediated GH resistance

— Anti-TNF therapy can restore growth dramatically; minimize chronic steroids (use budesonide, immunomodulators, biologics)

— Nutritional supplementation (sometimes NG feeds) restores growth velocity

— Optimize pancreatic enzyme replacement, fat-soluble vitamins, caloric density

— CFTR modulators (elexacaftor/tezacaftor/ivacaftor) improve growth

— Multifactorial: chronic anemia, iron overload (pituitary deposition), zinc deficiency

— Treat iron overload with chelation; screen for endocrinopathies

— Suppresses GH pulse amplitude and direct epiphyseal effects

— Use lowest effective dose, alternate-day dosing, steroid-sparing agents

Chronic kidney disease (CKD):

Chronic liver disease:

Inflammatory bowel disease:

Cystic fibrosis:

Sickle cell disease and thalassemia:

Glucocorticoid-treated children (asthma, JIA, nephrotic syndrome, IBD):

Step 3 management: In a CKD child failing to grow, fix acidosis, anemia, and nutrition before requesting GH — endocrine referral will reject the patient otherwise, and you'll lose months of growth potential.

Board pearl: Inhaled corticosteroids at standard pediatric asthma doses cause ~1 cm reduction in final adult height — clinically minor, but a frequent parental concern and Step 3 stem.

Special Populations — Adolescents, Adopted Children, and Demographic Subgroups

— Psychosocial impact (bullying, depression, body image) often warrants intervention even when CDGP is "benign"

— Boys: if no testicular enlargement by age 14, evaluate; consider testosterone priming

— Girls: if no breast development by age 13 or no menarche by age 15, evaluate

— Distinguish CDGP from hypogonadotropic hypogonadism (Kallmann syndrome — anosmia, low LH/FSH) — bone age, family history, and GnRH stim help; if uncertain, trial of priming and reassess

— Catch-up growth typically robust in first 1–2 years post-adoption with nutrition

— Screen for rickets, iron deficiency, parasites, hepatitis B, lead, TB, congenital infections

— Precocious puberty is common in formerly malnourished girls — monitor closely; can compromise adult height

— Use syndrome-specific growth charts (Down, Turner, Prader-Willi, achondroplasia)

— Standard CDC charts overdiagnose "short stature" in these populations

— Severe neglect → functional GH deficiency with low IGF-1 that normalizes within days of removal from the home

— Mandatory CPS report when suspected

— Growth resumes dramatically with placement in supportive environment — diagnostic and therapeutic

— Most achieve catch-up by age 2; if not, FDA-approves GH

— Monitor for metabolic syndrome later (developmental origins of disease)

Adolescents with CDGP:

Internationally adopted and refugee children:

Children with intellectual disability/syndromes:

Psychosocial short stature (emotional deprivation dwarfism):

Premature/SGA children:

Transgender adolescents: puberty blockade (GnRH agonists) and gender-affirming hormones affect growth trajectory; coordinate with adolescent medicine/endocrine.

Board pearl: Russell-Silver syndrome — triangular facies, hemihypertrophy, feeding difficulties, fasting hypoglycemia — responds well to GH; classic Step 3 vignette.

Complications and Adverse Outcomes

— Turner syndrome: aortic dissection (BAV/coarctation), premature ovarian insufficiency, hearing loss, autoimmune thyroiditis, celiac, diabetes — lifelong surveillance

— Hypothyroidism: myxedema, cognitive impairment, pericardial effusion

— Celiac: osteoporosis, lymphoma, infertility if untreated

— Cushing: osteoporosis, hypertension, diabetes, infection

— Craniopharyngioma: hypothalamic obesity, visual loss, panhypopituitarism, DI

— Idiopathic intracranial hypertension (pseudotumor cerebri) — headache, papilledema; usually within first 8 weeks; hold GH, restart at lower dose

— Slipped capital femoral epiphysis (SCFE) — hip/knee pain, limp; urgent ortho referral

— Scoliosis progression — monitor during rapid growth

— Insulin resistance, impaired glucose tolerance, frank diabetes — annual fasting glucose/HbA1c

— Central hypothyroidism unmasked — check free T4 after starting GH

— Adrenal insufficiency unmasked in panhypopituitarism

— Pancreatitis (rare)

— Cancer risk: no convincing increase in new primary malignancy; theoretical concern with active tumors → contraindicated

— Prader-Willi-specific: sudden death from OSA — mandatory pre-GH polysomnography

— Bullying, depression, anxiety, reduced quality of life

— Adult outcomes for untreated short stature: minor effect on income/relationships in most studies; psychosocial intervention often more impactful than centimeters gained

Untreated underlying disease complications:

GH therapy adverse effects:

Psychosocial complications:

Step 3 management: A child on GH presenting with new-onset limp or hip/knee pain — obtain frog-leg lateral hip X-ray immediately to rule out SCFE; do not attribute to growing pains.

Board pearl: GH-associated pseudotumor cerebri typically resolves with dose reduction; always perform fundoscopy if headache develops in a child on GH.

When to Escalate — Specialist Referral and Inpatient Triage

— Height <–2.5 SD or >2 SD below MPH

— Growth velocity <5 cm/yr (ages 4–puberty) or crossing percentile lines

— Low IGF-1/IGFBP-3 for age

— Abnormal bone age with otherwise unexplained short stature

— Suspected GH deficiency, hypothyroidism not improving on levothyroxine, Cushing, or pituitary mass

— Suspected Turner (positive karyotype)

— Disproportionate stature or dysmorphic features

— Family history of skeletal dysplasia

— Developmental delay with short stature

— Syndromic suspicion (Noonan, Russell-Silver, Prader-Willi)

— Positive celiac serology

— Chronic diarrhea, bloody stools, elevated calprotectin

— Abnormal Cr, persistent acidosis, proteinuria

— Pituitary or hypothalamic mass on MRI

— Visual field defects, headaches, multiple pituitary deficiencies

— New panhypopituitarism with adrenal crisis — IV hydrocortisone, fluids, electrolytes

— Severe malnutrition with refeeding risk — phosphate, magnesium, potassium monitoring

— New craniopharyngioma with vision loss or hydrocephalus — urgent neurosurgical evaluation

— Cushing crisis or thyroid storm workup

— Adolescents on GH transitioning to adult endocrinology — formal handoff at age 18–21 with retesting of GH axis (many "GHD" children have intact axes as adults)

Refer to pediatric endocrinology when:

Refer to genetics when:

Refer to GI when:

Refer to nephrology when:

Refer to neurosurgery/neuro-oncology when:

Inpatient admission rarely needed for short stature itself, but consider for:

Transitions of care:

CCS pearl: A previously healthy 8-year-old with growth deceleration, headaches, and bitemporal hemianopsia — order pituitary MRI urgently, consult neurosurgery and endocrine, give stress-dose hydrocortisone before surgery, and counsel family on lifelong pituitary replacement.

Key Differentials — Endocrine Causes of Short Stature

— Congenital (genetic, midline defects, pituitary stalk interruption) or acquired (tumor, radiation, trauma, infiltrative)

— Slow velocity, increased adiposity, "cherubic" appearance, delayed bone age, low IGF-1, failed stim test

— Acquired (Hashimoto most common) > congenital (missed on screen)

— Goiter, fatigue, constipation, delayed reflexes; TSH↑, free T4↓

— Dramatic catch-up on levothyroxine

— Linear growth arrest with weight gain is the pediatric hallmark — opposite of obese kids who are tall

— Exogenous steroids (most common) or endogenous (adrenal tumor, ACTH-secreting pituitary adenoma, ectopic ACTH rare in kids)

— Confirm with 24-hr UFC, late-night salivary cortisol, dexamethasone suppression

— Short stature, round facies, brachydactyly (short 4th/5th metacarpals), obesity, intellectual disability

— Low calcium, high phosphate, high PTH — end-organ resistance

— Hepatomegaly, growth failure, delayed puberty in chronically uncontrolled T1DM

— Initial tall stature → early epiphyseal fusion → short adult height

— Treat with GnRH agonists

— Bowed legs, rachitic rosary, widened wrists; low 25-OH D, high alk phos

Growth hormone deficiency (GHD):

Hypothyroidism:

Cushing syndrome:

Pseudohypoparathyroidism (Albright hereditary osteodystrophy):

Poorly controlled type 1 diabetes (Mauriac syndrome):

Precocious puberty:

Vitamin D deficiency/rickets:

Key distinction: Obese short child = endocrine (hypothyroid, Cushing, GHD, pseudohypoparathyroidism); thin short child = nutritional/GI/systemic (celiac, IBD, CKD, malnutrition). This single rule triages most Step 3 stems.

Board pearl: A child with growth failure and weight gain together has endocrine disease until proven otherwise — order TSH and screen for Cushing first.

Key Differentials — Genetic, Skeletal, and Systemic Causes

— Turner (45,X or mosaic): girls; webbed neck, lymphedema, cardiac anomalies — karyotype every short girl

— Noonan (autosomal dominant RAS-MAPK pathway): boys and girls; pulmonic stenosis, ptosis, pectus

— Down syndrome (trisomy 21): use Down-specific growth charts; screen for hypothyroidism, celiac

— Prader-Willi (15q11–13 paternal deletion/UPD): hypotonia, hyperphagia, hypogonadism

— Russell-Silver (11p15, UPD7): triangular facies, hemihypertrophy, fasting hypoglycemia

— DiGeorge (22q11.2 deletion): cardiac defects, hypocalcemia, immunodeficiency

— Achondroplasia (FGFR3): macrocephaly, frontal bossing, rhizomelic shortening, trident hand

— Hypochondroplasia: milder FGFR3

— Osteogenesis imperfecta (COL1A1/2): blue sclerae, fractures, hearing loss

— Mucopolysaccharidoses: coarse facies, organomegaly, skeletal dysplasia

— Celiac, IBD, CF, chronic infection (HIV, TB), CKD, congenital heart disease, sickle cell

— Look for organ-specific symptoms; treat underlying disease

— Caloric insufficiency (food insecurity, restrictive diets, eating disorders)

— Iron, zinc, vitamin D deficiency

— Functional reversible GH suppression; bizarre eating behaviors (foraging, polydipsia)

— Growth resumes within days of placement

— Chronic glucocorticoids, chemotherapy, cranial radiation, stimulants (modest)

Chromosomal/genetic syndromes:

Skeletal dysplasias (>400 entities; disproportionate stature):

Chronic systemic disease (proportionate short stature):

Nutritional:

Psychosocial (emotional deprivation):

Iatrogenic:

Key distinction: Proportionate short stature → endocrine, systemic, nutritional, chromosomal. Disproportionate short stature → skeletal dysplasia (measure U:L ratio and arm span).

Board pearl: Always check upper-to-lower segment ratio and arm span — this single measurement separates skeletal dysplasia (refer to genetics) from proportionate causes (endocrine/systemic workup).

Long-Term Plan and Secondary Prevention

— Turner syndrome: annual TSH, celiac screen, audiology, cardiac MRI q5 years, DEXA, fertility counseling, estrogen replacement through menopausal age

— GHD on GH: continue until growth plate fusion; retest GH axis as adult — true adult GHD warrants lifelong GH for metabolic, bone, cardiovascular health

— Craniopharyngioma: lifelong pituitary replacement, MRI surveillance, hypothalamic obesity management

— Celiac: strict gluten-free diet, annual TTG to verify adherence, DEXA, screen for other autoimmune disease

— Hypothyroidism: lifelong levothyroxine, TSH q6–12 months once stable

— Achondroplasia: monitor for foramen magnum stenosis (infancy MRI), sleep apnea, kyphosis, spinal stenosis, otitis media

— Begin transition planning at age 14

— Formal handoff at 18–21 to adult endocrinology, primary care, subspecialists

— Provide written summary of diagnosis, genetic results, medications, surveillance schedule

— Realistic expectations for adult height

— Adherence with daily injections

— Recognition of complications (SCFE pain, IIH headache, hypothyroid symptoms)

— Genetic counseling for heritable conditions

Lifelong follow-up by diagnosis:

Transition to adult care:

Patient/family education:

Vaccinations: standard schedule; live vaccines avoided during high-dose immunosuppression (Cushing, IBD biologics)

Bone health: calcium 1000–1300 mg/day, vitamin D 600–1000 IU/day, weight-bearing exercise, especially in Turner and steroid-treated children

Mental health: screen annually for depression, anxiety, body image concerns; refer for CBT

Step 3 management: At the adolescent's transition visit, formally retest the GH axis in childhood-onset GHD — up to two-thirds of children with "idiopathic GHD" have intact adult axes and can stop therapy.

Board pearl: Lifelong adult GH replacement improves body composition, bone density, lipids, and quality of life in true adult GHD — not just height.

Follow-Up, Monitoring, and Counseling

— Untreated short stature under observation: height/weight q3–6 months, growth velocity calculated, bone age q1–2 years

— On GH therapy: clinic visit q3–6 months; measure height, weight, Tanner stage, BP, spine; labs (IGF-1, TSH/T4, fasting glucose/HbA1c) q6–12 months

— On levothyroxine: TSH q6–8 weeks after dose change, then q6–12 months

— Celiac: TTG q6–12 months until normalized, then annually

— IGF-1 above age-normal range → reduce GH dose

— Growth velocity <2 cm/yr or near-final height → stop GH

— New headache, vision changes → IIH workup

— Hip/knee/groin pain → SCFE workup

— New back pain or progressive scoliosis → spine X-ray

— Polyuria/polydipsia → diabetes screen

— Daily GH injection technique, rotating sites, refrigeration

— Long-acting weekly somatrogon improves adherence for non-compliant adolescents

— Track via injection pens with electronic logs

— Adequate calories and protein

— Calcium, vitamin D, iron, zinc

— Gluten-free dietitian referral for celiac

— Anticipatory guidance about bullying, school accommodations

— Peer support groups (Magic Foundation, Human Growth Foundation, Turner Syndrome Society)

— Sports participation: encouraged with modifications for skeletal dysplasia or cardiac anomalies (Turner — restrict from high-static activities if aortic dilation)

— PT for hypotonia (Prader-Willi), spinal stenosis (achondroplasia)

— OT for fine motor delays in syndromes

Routine monitoring intervals:

Monitoring parameters and red flags:

Adherence counseling:

Nutritional counseling:

Psychosocial support:

Rehab considerations:

Step 3 management: Document shared decision-making when initiating GH for ISS — modest height gain (3–7 cm), high cost, daily injections — and revisit annually whether continued therapy aligns with family goals.

Board pearl: Growth velocity (cm/yr) is more sensitive than absolute height for detecting pathology and monitoring response to therapy.

Ethical, Legal, and Patient Safety Considerations

— High cost ($20,000–$60,000/year), daily injections, modest gains for non-GHD indications

— Assent from child ≥7 years — adherence improves when child is part of decision

— Discuss alternatives (observation, psychosocial support) and right to decline

— Document realistic expectations — final adult height gain for ISS averages only 3–7 cm

— Adolescents may decline ongoing GH; respect autonomy after thorough discussion

— Document refusal and continue surveillance

— Psychosocial short stature/emotional deprivation dwarfism is a form of neglect — CPS report is mandatory under state law for all healthcare providers

— Document objective findings (growth chart, eating behaviors, response to hospitalization)

— Childhood-onset hypopituitarism patients lost to follow-up at age 18 are at risk for adrenal crisis from undocumented steroid dependence — provide MedicAlert bracelet, emergency hydrocortisone instructions, written transition summary

— Failure to retest GH axis at transition leads to inappropriate lifelong therapy or premature discontinuation

— GH access varies by insurance; non-deficient indications often denied

— Advocate via prior authorization with growth velocity, IGF-1, bone age data

— Food insecurity is an underrecognized "social determinant" cause of short stature — screen with Hunger Vital Signs tool

— Aromatase inhibitors, GnRH agonists to extend growth window are not FDA-approved for ISS — discuss experimental nature, obtain consent

— Karyotype/microarray findings (e.g., Turner mosaicism, 22q11) have implications for siblings — offer genetic counseling

Informed consent and assent for GH therapy:

Pediatric autonomy and emerging adolescent decision-making:

Mandatory reporting:

Transition-of-care safety:

Health equity:

Off-label use:

Genetic privacy:

Step 3 management: A pediatrician suspecting psychosocial dwarfism must file a CPS report; this is non-negotiable, even before the diagnosis is fully confirmed, and is legally protected from family retaliation in all states.

Board pearl: Document shared decision-making conversations for GH therapy — Step 3 ethics stems frequently test parental requests for GH in children with normal-variant short stature; the answer is reassurance and observation, not therapy.

High-Yield Associations and Rapid-Fire Facts

Turner syndrome: karyotype every short girl, even without classic features; cardiac MRI, audiology, thyroid surveillance.

Russell-Silver: triangular face, hemihypertrophy, fasting hypoglycemia.

Achondroplasia: FGFR3 gain-of-function, autosomal dominant, paternal age effect; vosoritide therapy.

Noonan: PTPN11; pulmonic stenosis, lymphatic dysplasia, "male Turner."

Prader-Willi: hypotonia → hyperphagia; GH improves height and body composition; mandatory pre-GH polysomnography.

Laron syndrome: GH receptor mutation; high GH, low IGF-1; treat with mecasermin, not GH.

Constitutional delay: delayed bone age + delayed puberty + late-bloomer family history = reassure.

Familial short stature: normal bone age, tracks MPH, normal puberty.

Psychosocial dwarfism: bizarre eating, growth resumes in hospital; mandatory CPS report.

Cushing in kids: growth arrest + weight gain (opposite of healthy obese child).

Celiac: TTG-IgA + total IgA; biopsy confirms; gluten-free diet catch-up.

Hypothyroidism: TSH↑, T4↓; levothyroxine catch-up dramatic.

GHD: low IGF-1, failed stim test (two agents, peak <10), MRI for stalk interruption.

SHOX deficiency: Madelung deformity; FDA-approved GH indication.

CKD growth failure: fix acidosis, anemia, nutrition first; GH dose higher than GHD.

Steroid-induced growth failure: alternate-day dosing, steroid-sparing agents.

Bone age younger than chronologic: delayed = CDGP, endocrine, chronic illness; equal = familial or normal; advanced = precocious puberty.

Mid-parental height formula: boys (M+F+13)/2; girls (M+F–13)/2; ±8.5 cm range.

Growth velocity <5 cm/yr ages 4–puberty: pathologic until proven otherwise.

GH side effects: IIH, SCFE, scoliosis, insulin resistance, unmasked central hypothyroidism/adrenal insufficiency.

Vosoritide: CNP analog for achondroplasia ≥5 years.

Aromatase inhibitors: off-label to delay epiphyseal closure in CDGP boys.

Board pearl: Short, obese child = endocrine; short, thin child = systemic/nutritional — single highest-yield rule for short stature stems.

Board Question Stem Patterns

Stem 1 — Familial short stature: 8-year-old girl, height <3rd %ile, growth velocity 6 cm/yr, bone age = chronologic, both parents short, normal Tanner. → Reassurance, plot serially, no labs needed beyond initial screen.

Stem 2 — Constitutional delay: 14-year-old boy, height at 5th %ile but Tanner 1, bone age 12, father had growth spurt at 16. → CDGP; observe or short-course testosterone for psychosocial distress.

Stem 3 — Turner syndrome: 11-year-old girl, height <3rd %ile, no breast development, wide-spaced nipples, cubitus valgus. → Karyotype; expect 45,X mosaic; start GH, estrogen at age 11–12, cardiac evaluation.

Stem 4 — Hypothyroidism: 9-year-old, slowing growth over 2 years, weight gain, constipation, cold intolerance, goiter. → TSH elevated → levothyroxine, catch-up growth.

Stem 5 — Cushing: 10-year-old, growth arrest + weight gain, central obesity, striae, hypertension, on chronic prednisone for asthma. → Iatrogenic Cushing; taper steroids, switch to inhaled.

Stem 6 — Craniopharyngioma: 7-year-old, growth deceleration, headaches, bitemporal hemianopsia. → Pituitary MRI, neurosurgery, replace cortisol before levothyroxine before GH.

Stem 7 — Celiac: 6-year-old, short stature, chronic diarrhea, abdominal distention, iron-deficiency anemia. → TTG-IgA + total IgA, EGD biopsy, gluten-free diet.

Stem 8 — Achondroplasia: infant with macrocephaly, frontal bossing, rhizomelic limb shortening. → FGFR3 testing, monitor foramen magnum, consider vosoritide ≥5 years.

Stem 9 — Psychosocial dwarfism: 5-year-old, severely short, bizarre eating (foraging, gorging), neglected; growth resumes during hospitalization. → CPS report, social work.

Stem 10 — SCFE on GH: 12-year-old on GH presents with hip pain and limp. → Frog-leg lateral hip X-ray, hold GH, ortho consult.

Stem 11 — Laron syndrome: child with high GH, low IGF-1, failed IGF-1 generation test. → Mecasermin (recombinant IGF-1), not GH.

Stem 12 — Idiopathic short stature parental request: healthy 10-year-old, height 10th %ile, normal velocity, parents request GH. → Reassurance and observation; not FDA criteria.

Board pearl: Stems describing "weight gain plus growth arrest" → endocrine; "weight loss plus growth arrest" → GI/systemic; "normal weight, delayed bone age, late-bloomer family" → CDGP; "normal everything, parents are short" → familial.

One-Line Recap

Short stature workup hinges on three measurements — accurate serial heights to calculate growth velocity, a bone age X-ray, and the mid-parental height — which together separate the 80% with familial short stature or constitutional delay (reassurance) from the 20% with pathology (endocrine, GI, renal, genetic, or psychosocial) requiring targeted workup and treatment.

The three-step triage: plot serial heights + calculate velocity → bone age + MPH → screening labs (CBC, CMP, ESR, TSH/T4, IGF-1, TTG, UA, karyotype in girls).

The single highest-yield rule: short + obese = endocrine (hypothyroid, Cushing, GHD, pseudohypoparathyroidism); short + thin = systemic/nutritional (celiac, IBD, CKD, malnutrition); short + normal weight + delayed bone age + late-bloomer family = CDGP.

Treatable causes never to miss: hypothyroidism (TSH), celiac (TTG-IgA + total IgA), Turner syndrome (karyotype every short girl), Cushing (24-hr UFC), GH deficiency (IGF-1 → stim test → MRI), psychosocial deprivation (CPS report).

GH therapy: FDA-approved for GHD, Turner, SGA without catch-up, ISS, SHOX, Prader-Willi, Noonan, CKD; monitor IGF-1, TSH, glucose; watch for IIH, SCFE, scoliosis, unmasked adrenal insufficiency; retest axis at adult transition.

Step 3 management essence: distinguish normal variants from pathology with cheap data first (growth chart, bone age, MPH), treat reversible causes early, refer specialists for confirmed pathology, document shared decision-making for GH in non-deficient children, and never forget the mandatory CPS report for suspected psychosocial dwarfism.